Healthcare / Medical DevicesNSE
$412.15
-8.40 (-2.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $39.1M · quality 30.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
5.2x
↓EV/EBITDA
4.7x
↓ROE
10.0%
↑Gross Margin
28.9%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-24.1%
FCF CAGR
—
FCF margin
751.8%
FCF / Net income
2.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $245.7M · net income $870.1M · FCF $1.85B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $245.7M | $245.7M | $324.4M | $432.1M | $561.6M |
| Net Income | $870.1M | $870.1M | $-1.96B | $-444.7M | $5.14B |
| EBITDA | $957.5M | $957.5M | $-1.87B | $-392.4M | $5.97B |
| EPS | 79.49 | 79.49 | -179.37 | -40.62 | 469.87 |
| Gross Margin | 28.9% | 28.9% | 28.7% | 31.2% | 31.3% |
| Operating Margin | -4.0% | -4.0% | 10.2% | 17.2% | 19.9% |
| Net Margin | 354.2% | 354.2% | -605.3% | -102.9% | 915.9% |
| Cash Flow | |||||
| Free Cash Flow | $1.85B | $1.85B | $39.1M | $-83.4M | $-595.9M |
| Returns | |||||
| ROE | 10.0% | 10.0% | -22.7% | -4.2% | 47.9% |
| Valuation | |||||
| P/E | 5.18 | 5.18 | — | — | 1.11 |
| EV/EBITDA | 4.71 | 4.71 | — | — | 0.96 |
| P/B | 0.52 | 0.52 | 0.49 | 0.41 | 0.53 |
| Growth & Yield | |||||
| Revenue Growth | -24.3% | -24.3% | -24.9% | -23.1% | — |
| EPS Growth | 144.3% | 144.3% | -341.6% | -108.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
3Y implied EPS CAGR
-22.8%
EPS terminal req.
$36.57
Spread vs growth
167.1%
5Y implied EPS CAGR
-11.1%
EPS terminal req.
$44.25
Spread vs growth
155.4%
10Y implied EPS CAGR
-1.1%
EPS terminal req.
$71.27
Spread vs growth
145.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+66.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-179.37 → 79.49
Residual
+66.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.